Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, an implant for the reduction of mobile spinal fractures and restoration of the balance of the spinal column. The Company currently has 65 members on its staff and it has its own sales teams in France, Germany, Austria, Italy, Spain, as well as distributors in European area, in Asia area, in LATAM areas, in the Middle East, in South Africa and in the following countries where the product is currently being registered: Mexico, Bosnia and Herzegovina, Vietnam, Iran. Moreover, it was already registered in Australia. More information on www.vexim.com